MedTrace Logo

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

NCT07392866 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-09

No results posted yet for this study

Summary

To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

SH006

15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Bevacizumab

15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Oxaliplatin injection

85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Capecitabine

1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

DRUG

Regorafenib

160 mg orally once daily for 21 days continuous dosing followed by a 7-day break of each 28-day cycle

Sponsors & Collaborators

  • Nanjing Sanhome Pharmaceutical, Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2030-03-01
Completion
2030-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07392866 on ClinicalTrials.gov